Prof. Dr. Ron van Schaik, PhD is a registered European specialist Laboratory medicine (2003) and a Full Professor of Pharmacogenetics (2013). He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, The Netherlands. He is Director of the International (IFCC) Reference Center for Pharmacogenetics and he leads the Unit Research & Development of the Dept. Clinical Chemistry. He is also responsible for laboratory testing in Emergency Medicine and Cardiology, and is involved in development of new prostate cancer biomarkers.

His research focuses on clinical implementation of Pharmacogenetics. Specific targets are Transplantation/immunosuppression (cyclosporin, tacrolimus, MMF), Oncology (paclitaxel, docetaxel, tamoxifen), Pain (morphine, tramadol), Psychiatry (antidepressants, antipsychotics),   HIV (efavirenz, nevirapine) and Anticoagulation (coumarins). He has published over 175 articles in this field of pharmacogenetics. Prof van Schaik participated in 12 grants with a total value of € 7,8 million.
Prof van Schaik has given over 200 invited lectures. He participates in national and international advisory committees on pharmacogenetics, a.o. IFCC Task Force Pharmacogenetics (Chair), IATDMCT Pharmacogenetics Committee (chair), Dutch Task Force Pharmacogenetics (NVKC; chair), Dutch Committee on Molecular Biological Diagnostics (CMBD; chair), IUPHAR working group Pharmacogenetics (member), European Pharmacogenetics Research Network (Steering Committee), European Society for Personalized Medicine (EUSPM; treasurer), European Society for Pharmacogenetics and Theranostics (ESPT; Chair Scientific & Clinical Implementation Division), AACC Personalized Medicine Division (founding member) and the Pharmacogenetics Working Group of the European Medicine Agency (EMA). In 2001, he received the Ortho Clinical Diagnostics Award for Outstanding Research, in 2009 the AACC Outstanding Speaker Award, and in 2010 the AACC/Mol Pathology Award for Outstanding Scientific Research.  

Prof. Dr. Ron van Schaik, PhD is a registered European specialist Laboratory medicine (2003) and a Full Professor of Pharmacogenetics (2013). He is working at the Dept. Clinical Chemistry at the Erasmus University Medical Center Rotterdam, The Netherlands. He is Director of the International (IFCC) Reference Center for Pharmacogenetics and he leads the Unit Research & Development of the Dept. Clinical Chemistry. He is also responsible for laboratory testing in Emergency Medicine and Cardiology, and is involved in development of new prostate cancer biomarkers.
His research focuses on clinical implementation of Pharmacogenetics. Specific targets are Transplantation/immunosuppression (cyclosporin, tacrolimus, MMF), Oncology (paclitaxel, docetaxel, tamoxifen), Pain (morphine, tramadol), Psychiatry (antidepressants, antipsychotics),   HIV (efavirenz, nevirapine) and Anticoagulation (coumarins). He has published over 175 articles in this field of pharmacogenetics. Prof van Schaik participated in 12 grants with a total value of € 7,8 million.
Prof van Schaik has given over 200 invited lectures. He participates in national and international advisory committees on pharmacogenetics, a.o. IFCC Task Force Pharmacogenetics (Chair), IATDMCT Pharmacogenetics Committee (chair), Dutch Task Force Pharmacogenetics (NVKC; chair), Dutch Committee on Molecular Biological Diagnostics (CMBD; chair), IUPHAR working group Pharmacogenetics (member), European Pharmacogenetics Research Network (Steering Committee), European Society for Personalized Medicine (EUSPM; treasurer), European Society for Pharmacogenetics and Theranostics (ESPT; Chair Scientific & Clinical Implementation Division), AACC Personalized Medicine Division (founding member) and the Pharmacogenetics Working Group of the European Medicine Agency (EMA). In 2001, he received the Ortho Clinical Diagnostics Award for Outstanding Research, in 2009 the AACC Outstanding Speaker Award, and in 2010 the AACC/Mol Pathology Award for Outstanding Scientific Research.